| Yuying Jiang, MD | |
|
1912 Hayes Ave, Sandusky, OH 44870-4736 | |
| (419) 557-7400 | |
| Not Available |
| Full Name | Yuying Jiang |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 34 Years |
| Location | 1912 Hayes Ave, Sandusky, Ohio |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922327394 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 35123971 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Genesis Hospital | Zanesville, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greater Cincinnati Pathologists Inc | 9032011630 | 21 |
News Archive
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.
Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
An international group of researchers, with the participation of the members of the University of Seville and the Andalusian Centre of Molecular Biology and Regenerative Medicine has just published a study in the prestigious review Science, in which they describe a new methodology for making tumor cells behave when submitted to chemotherapy, which, in the hope of new treatments, continues to be a fundamental tool in the fight against cancer.
› Verified 9 days ago
| Entity Name | Greater Cincinnati Pathologists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407844657 PECOS PAC ID: 9032011630 Enrollment ID: O20040123000619 |
News Archive
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.
Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
An international group of researchers, with the participation of the members of the University of Seville and the Andalusian Centre of Molecular Biology and Regenerative Medicine has just published a study in the prestigious review Science, in which they describe a new methodology for making tumor cells behave when submitted to chemotherapy, which, in the hope of new treatments, continues to be a fundamental tool in the fight against cancer.
› Verified 9 days ago
| Entity Name | Preferred Associates Of Pathology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588689434 PECOS PAC ID: 6507899622 Enrollment ID: O20050918000030 |
News Archive
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.
Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
An international group of researchers, with the participation of the members of the University of Seville and the Andalusian Centre of Molecular Biology and Regenerative Medicine has just published a study in the prestigious review Science, in which they describe a new methodology for making tumor cells behave when submitted to chemotherapy, which, in the hope of new treatments, continues to be a fundamental tool in the fight against cancer.
› Verified 9 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.
Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
An international group of researchers, with the participation of the members of the University of Seville and the Andalusian Centre of Molecular Biology and Regenerative Medicine has just published a study in the prestigious review Science, in which they describe a new methodology for making tumor cells behave when submitted to chemotherapy, which, in the hope of new treatments, continues to be a fundamental tool in the fight against cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Yuying Jiang, MD P.o Box 1188, Bowling Green, OH 43402-1188 Ph: (419) 861-7052 | Yuying Jiang, MD 1912 Hayes Ave, Sandusky, OH 44870-4736 Ph: (419) 557-7400 |
News Archive
A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.
Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.
Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.
Invatec, a comprehensive innovator of interventional products, today launched its latest self-expanding peripheral stent system, Maris Plus in new 6, 7 and 8mm diameters, ideal for interventions involving the superficial femoral arteries (SFA). The 9, 10 and 12mm diameters of the stent are already marketed for the iliac artery.
An international group of researchers, with the participation of the members of the University of Seville and the Andalusian Centre of Molecular Biology and Regenerative Medicine has just published a study in the prestigious review Science, in which they describe a new methodology for making tumor cells behave when submitted to chemotherapy, which, in the hope of new treatments, continues to be a fundamental tool in the fight against cancer.
› Verified 9 days ago
Richard S Scarborough, D.O. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1912 Hayes Ave, Sandusky, OH 44870 Phone: 419-557-7189 Fax: 419-557-7109 | |
Rina Siddiqui, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 1111 Hayes Ave, Sandusky, OH 44870 Phone: 419-557-7400 | |
Dr. Jianlan Sun, M.D., PH.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1111 Hayes Ave, Sandusky, OH 44870 Phone: 419-557-7400 Fax: 716-859-1958 |